WO2000007634A1 - Contact lens and ophthalmic solutions - Google Patents
Contact lens and ophthalmic solutions Download PDFInfo
- Publication number
- WO2000007634A1 WO2000007634A1 PCT/US1999/017853 US9917853W WO0007634A1 WO 2000007634 A1 WO2000007634 A1 WO 2000007634A1 US 9917853 W US9917853 W US 9917853W WO 0007634 A1 WO0007634 A1 WO 0007634A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- contact lens
- solution
- group
- acid
- lens solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L12/143—Quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/382—Vegetable products, e.g. soya meal, wood flour, sawdust
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/22—Organic compounds
- C11D7/40—Products in which the composition is not well defined
- C11D7/44—Vegetable products
Definitions
- the present invention relates to contact lens and ophthalmic solutions and in particular relates to methods to disinfect and clean soft and rigid gas permeable (RGP) contact lenses, effectively and safely while maintaining convenience and comfort for the contact lens wearer.
- RGP gas permeable
- contact lenses are made of hydrogels causing them to be soft so that they can be comfortably worn.
- contact lenses were either hard plastic (PMMA) or RGP and required the contact lens wearing patient to adjust to the uncomfortable sensation of a foreign body in the eye.
- PMMA hard plastic
- RGP hard plastic
- the advent of soft contact lenses has resulted in an increased adoption of contact lenses by the general population.
- Contact lenses are commonly worn on a daily basis and kept in a storage case/solution during the night hours or whenever they are not being worn.
- microorganisms as well as biomolecules such as lipids, proteins, etc. can become adhered to the contact lenses and thus transferred to the storage case/solution.
- a tear film that contains proteins, lipids, and even microorganisms, which represent the natural flora of the ocular surface, covers the surface of the eye. Any of these components found in the tear film or on the external surface of the eye or the surrounding skin can be carried into the storage case/solution on the contact lens.
- Some of the microorganisms that may be transferred from the eye or fingers to the storage case/solution may multiply therein and may later be pathogenic to the human cornea or other ocular structures.
- the contact lens When the contact lens is returned to the eye following its overnight soaking period, it is possible for these pathogens to be applied to the surface of the eye.
- human tears contain natural anti-microbial agents, a pathogen-bearing lens in contact with the cornea of the eye can serve as a reservoir of infection that might overcome the eye's natural defenses. This is especially the case for soft contact lens as the material tends to uptake the microorganisms.
- the result of microbial growth — bacterial, protozoan or even fungal — can cause damage to the eye resulting in impaired vision and even blindness. Therefore, contact lenses should be daily disinfected to eliminate pathogenic organisms, usually overnight, i.e., six to eight hours, to protect the wearer's eyes from infection.
- contact lens solutions typically include antimicrobial substances as well as cleaning (active against both lipids and proteins), wetting and other agents for the disinfection and cleaning of contact lenses during storage after wear.
- These solutions generally have sufficient microbicidal activity that the numbers of potentially pathogenic microorganisms are reduced to a prescribed level during the overnight soaking period.
- Disinfection agents typically used for other applications such as hard surface disinfection, instrument disinfection, topical skin disinfection, etc. are not necessarily applicable to contact lens and ophthalmic solutions.
- the high concentration used and aggressive nature of many of these agents are unsuitable for use with contact lenses due to interaction or damage to the lens or irritation to ocular tissue.
- "Strong" disinfecting agents are compounds such as thimerasol, chlorhexidine, hydrogen peroxide, and benzalkonium chloride.
- three (3%) percent hydrogen peroxide instilled directly in the eye or a lens soaked in hydrogen peroxide and applied to the eye will result in pain and severe irritation.
- prior art answers to the problem of irritation are disclosed in U.S.
- This approach has found some level of acceptance among contact lens wearers. However, acceptance has remained limited, because of the multiple steps of disinfection, neutralization, and rinsing are not convenient to the wearer. More importantly, the potential exists for the neutralization and rinsing steps to be completed incorrectly (non-compliance) leading to the potential for some residual hydrogen peroxide to come in contact with the surface of the eye with the onset of severe stinging and irritation.
- MPS multipurpose solutions
- U.S. Patents 4,407,791, 4,525,346, 4,758,595, 4,820,352, 4,836,956, 5,422,073, 5,560,186, 5,593,637, and 5,756,045 have largely supplanted hydrogen peroxide systems in the marketplace because they are far more convenient than the hydrogen peroxide systems.
- the wearer need only purchase and use a single solution leading to advantages in cost and convenience.
- the challenge of disinfection and cleaning without harm to the eye or the lens is particularly acute with the MPS products, however, since all of the various activities, e.g., wetting, contaminant dispersion, and disinfection, are required to co-exist in a single solution without antagonistic effects of one component on the activity of another. Furthermore, because the MPS can be instilled directly into the eye, the active anti-microbial component of these solutions must provide the required degree of pathogen reduction while being free of irritating or damaging sequelae to the surface and the anterior segment of the eye or to the contact lens itself. There is no opportunity with an MPS to neutralize or rinse away the anti-microbial agent prior to applying the contact lens to the eye.
- bioflavonoids can be employed in contact lens care products as natural
- bioflavonoids they are natural plant products, the majority of bioflavonoids are complex combinations
- agent For example, if the agent has effected a reduction in the concentration of a
- Candida albicans a yeast
- Fusarium a yeast
- solani (a mold), Pseudomonas aeruginosa (a Gram-negative bacterium), Staphylococcus
- solution possess a tonicity and pH within the physiological range, e.g., 200-350
- osmotic agents are often added.
- the simplest osmotic agent is sodium chloride since this is a
- mannitol or other osmotic agents may also be added to replace some or all of the sodium
- borate borate (boric acid, sodium borate, potassium tetraborate, potassium metaborate and mixtures), bicarbonate, and tromethamine and
- nitrogen-containing buffers such as ACES, BES, BICINE, BIS-Tris,
- Tricine can be used to ensure a physiologic pH between about pH 6.5 and 8.5.
- viscosity building agents such as polyethylene glycol, surfactants,
- polysorbates polyoxyethylenes and certain phosphonates may be added to ensure that
- Sequestering agents such as ethylenediaminetetraacetic
- EDTA ethylene glycol dimethyroxine
- phosphonates citrate, gluconate and tartarate are also common additives
- lens solutions particularly the MPS solutions, has been to find disinfection agents with
- the present invention concerns the unexpected discovery that the disinfectant
- aqueous solution and can coexist in an formulation with the variety of cleaning, tonicity,
- the basic active ingredient formulation of the present invention comprises an
- BDT effective concentration of BDT (preferably 1 to 100 parts per million), either alone or
- anti-microbial compounds show anti-microbial and cleaning activity. It has also been discovered that some of these anti-microbial compounds act in a synergistic and or complementary manner with other anti-microbial compounds, such as BDT, and thus enhances their anti-microbial action.
- the potential range of these anti-microbial compounds includes glycosides, alkaloids, phenolics (anthocyanins, quinones, flavonols and flavonoids, etc.), and terpenoids (including phytosterols and carotenoids).
- anti-microbial compounds Of particular interest are the following anti-microbial compounds; Allicin, Aucubin, Berberine, Bilberry extract, Caffeic Acid, Chlorogenic Acid, Echinacea extract, Ferulic Acid, Hydrastine, Lipoic Acid, Naringin, Oleuropein, Proanthocyanidins, Quercetin, and Rutin as stand alone disinfection agents or in combination with other anti-microbial agents.
- saponins can be used as a natural plant surface active or cleaning agents in lens solutions. Specifically triterpenoid saponins and steriod saponins are particularly effective in contact lens or ophthalmic solutions. Also, a wide range of other comfort and cleaning enhancers can be added to the basic solution without adverse affects on the activity of these natural compounds or combinations. Suitable additives include, but are not limited to, various wetting, buffering, osmotic, sequestering, and comfort enhancing agents can be added to enhance the final formulation. .
- Table 4 shows the effect of adding 0.2% Glycerin to 25 ppm BDT and 250 ppm chlorogenic acid with borate buffer. In terms of microbiological disinfection this solution is very effective.
- the addition of Glycerin a naturally occurring compound has essentially no effect on the disinfectant properties. There is evidence that Glycerin can reduce any minor toxic effects that a disinfectant agent might have on mammalian cells.
- Table 5 shows the effect of adding 0.2% Decanedioic Acid and 0.2% Glycerin to a formulation consisting of 25 ppm BDT and 1000 ppm Caffeic Acid in Borate Buffer. Decanedioic Acid is believed to improve the ocular comfort of contact lens solutions. As show in Table 5, there is no negative impact on anti-microbial activity with both Glycerin and Decanedioic Acid.
- Table 8-a shows the anti-microbial activity of two naturally-occurring
- Table 8-b shows the anti-microbial activity of a third naturally-occurring
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU54686/99A AU764906B2 (en) | 1998-08-06 | 1999-08-05 | Contact lens and ophthalmic solutions |
DE69916620T DE69916620D1 (en) | 1998-08-06 | 1999-08-05 | CONTACT LENS AND OPHTHALMIC SOLUTIONS |
CA002339635A CA2339635A1 (en) | 1998-08-06 | 1999-08-05 | Contact lens and ophthalmic solutions |
EP99940927A EP1102602B1 (en) | 1998-08-06 | 1999-08-05 | Contact lens and ophthalmic solutions |
AT99940927T ATE264697T1 (en) | 1998-08-06 | 1999-08-05 | CONTACT LENS AND OPHTHALMIC SOLUTIONS |
JP2000563316A JP2002522120A (en) | 1998-08-06 | 1999-08-05 | Contact lens solution and ophthalmic solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/130,542 | 1998-08-06 | ||
US09/130,542 US6162393A (en) | 1998-08-06 | 1998-08-06 | Contact lens and ophthalmic solutions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000007634A1 true WO2000007634A1 (en) | 2000-02-17 |
Family
ID=22445177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/017853 WO2000007634A1 (en) | 1998-08-06 | 1999-08-05 | Contact lens and ophthalmic solutions |
Country Status (8)
Country | Link |
---|---|
US (2) | US6162393A (en) |
EP (2) | EP1336415A3 (en) |
JP (1) | JP2002522120A (en) |
AT (1) | ATE264697T1 (en) |
AU (1) | AU764906B2 (en) |
CA (1) | CA2339635A1 (en) |
DE (1) | DE69916620D1 (en) |
WO (1) | WO2000007634A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002161038A (en) * | 2000-09-14 | 2002-06-04 | Hayashibara Biochem Lab Inc | Ophthalmic pharmaceutical composition |
JP2002326941A (en) * | 2001-05-01 | 2002-11-15 | Naomasa Morita | Agent for ophthalmic use |
EP1339418A1 (en) * | 2000-11-08 | 2003-09-03 | Bio-Concept Laboratories | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
EP1353709A1 (en) | 2001-01-12 | 2003-10-22 | Novartis AG | Lens care product containing dexpanthenol |
WO2003086442A3 (en) * | 2002-04-04 | 2004-03-18 | Natural Disinfectant Technolog | Ophthalmic, pharmaceutical and other healthcare preparations with naturally occuring plant compounds, extracts and derivatives |
JP2004526186A (en) * | 2000-11-08 | 2004-08-26 | バイオ−コンセプト・ラボラトリーズ | Improved ophthalmic and contact lens solutions containing vitamin B forms |
WO2006039460A2 (en) * | 2004-09-29 | 2006-04-13 | Bausch & Lomb Incorporated | Contact lens with biocidal activity, process of manufacture, use of the contact lens, and kit |
EP1905443A1 (en) * | 2005-06-08 | 2008-04-02 | Cellex K.K. | Liquid for preventing tissue adhesion and method of preventing tissue adhesion |
US9308264B2 (en) | 2000-11-08 | 2016-04-12 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
US9492582B2 (en) | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
US9913474B2 (en) | 2000-11-08 | 2018-03-13 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432893B1 (en) * | 1998-08-21 | 2002-08-13 | Senju Pharmaceutical Co., Ltd. | Method for removal of protein from contact lenses |
US6482799B1 (en) * | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
US8256135B2 (en) * | 1999-05-28 | 2012-09-04 | Thermapure, Inc. | Method for removing or treating harmful biological and chemical substances within structures and enclosures |
US8272143B1 (en) | 2002-02-20 | 2012-09-25 | David Hedman | System and process for removing or treating harmful biological and organic substances within structures and enclosures |
US20050013727A1 (en) * | 2002-12-05 | 2005-01-20 | Hedman David E. | System and process for removing or treating harmful biological and organic substances within an enclosure |
US20110064607A1 (en) * | 1999-05-28 | 2011-03-17 | Thermapure, Inc. | Method for removing or treating harmful biological organisms and chemical substances |
US7837932B2 (en) * | 1999-05-28 | 2010-11-23 | Thermapure, Inc. | Method for removing or treating harmful biological organisms and chemical substances |
US8221678B2 (en) * | 2002-02-20 | 2012-07-17 | Hedman David E | System and process for removing or treating harmful biological and organic substances within an enclosure |
US7678836B2 (en) * | 1999-11-04 | 2010-03-16 | Fxs Ventures, Llc | Method for rendering a contact lens wettable |
US7067547B1 (en) * | 1999-11-04 | 2006-06-27 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions comprising imidazole |
US8557868B2 (en) * | 2000-11-04 | 2013-10-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions using low molecular weight amines |
US20070104744A1 (en) * | 2000-11-08 | 2007-05-10 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing forms of vitamin b |
US20060148665A1 (en) * | 2000-11-08 | 2006-07-06 | Bioconcept Laboratories | Ophthalmic and contact lens solutions containing forms of vitamin b |
US20060127496A1 (en) * | 2000-11-08 | 2006-06-15 | Bioconcept Laboratories | L-histidine in ophthalmic solutions |
US20070110782A1 (en) * | 2000-11-08 | 2007-05-17 | Fxs Ventures, Llc | L-histidine in ophthalmic solutions |
MXPA03004816A (en) * | 2000-11-29 | 2003-09-25 | Novartis Ag | Aqueous disinfecting systems. |
US7405235B2 (en) * | 2001-05-04 | 2008-07-29 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
JP4933730B2 (en) * | 2001-05-04 | 2012-05-16 | パラテック ファーマシューティカルズ インコーポレイテッド | Transcription factor modulating compounds and methods of use thereof |
US6617291B1 (en) * | 2001-11-08 | 2003-09-09 | Francis X. Smith | Ophthalmic and contact lens solutions |
US20030133905A1 (en) * | 2001-12-20 | 2003-07-17 | Zhenze Hu | Composition for treating contact lenses in the eye |
WO2004024855A1 (en) * | 2002-09-09 | 2004-03-25 | Novartis Ag | Contact lens care product containing natural plant extracts |
JP4500261B2 (en) | 2003-01-21 | 2010-07-14 | 千寿製薬株式会社 | 2-Amino-3- (4-bromobenzoyl) phenylacetic acid-containing aqueous solution |
US7939501B2 (en) * | 2003-04-15 | 2011-05-10 | Smith Francis X | Ophthalmic and contact lens solutions containing peptides as preservative |
US20040229825A1 (en) * | 2003-05-13 | 2004-11-18 | Tomihiko Higuchi | Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant |
NL1024513C2 (en) * | 2003-10-10 | 2005-04-12 | Jon Holding B V | Method for disinfecting and / or cleaning contact lenses using a liquid aqueous composition as well as composition for applying them. |
CA2545962A1 (en) * | 2003-12-09 | 2005-07-07 | Alcon, Inc. | Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions |
US20060160799A1 (en) | 2004-04-23 | 2006-07-20 | Alekshun Michael N | Transcription factor modulating compounds and methods of use thereof |
US7632869B2 (en) * | 2004-05-24 | 2009-12-15 | Bausch & Lomb Incorporated | Antimicrobial compositions and uses thereof |
ITMI20042414A1 (en) * | 2004-12-17 | 2005-03-17 | Indena Spa | FORMULATION FOR THE TREATMENT OF AFFECTIONS OF THE FIRST RESPIRATORY ROUTES |
SG177132A1 (en) | 2005-02-14 | 2012-01-30 | Johnson & Johnson Vision Care | A comfortable ophthalmic device and methods of its production |
US7282178B2 (en) * | 2005-06-03 | 2007-10-16 | Bausch & Lomb Incorporated | Composition and method for cleaning lipid deposits on contact lenses |
US20060276359A1 (en) * | 2005-06-03 | 2006-12-07 | Bausch & Lomb Incorporated | Composition and method for cleaning lipid deposits on contact lenses |
US20060275173A1 (en) * | 2005-06-03 | 2006-12-07 | Bausch & Lomb Incorporated | Method for cleaning lipid deposits on silicone hydrogel contact lenses |
US9052529B2 (en) | 2006-02-10 | 2015-06-09 | Johnson & Johnson Vision Care, Inc. | Comfortable ophthalmic device and methods of its production |
US20070293410A1 (en) * | 2006-06-15 | 2007-12-20 | Surowiak Richard J | Contact lens and method for preventing contact lens intolerance |
US20080124404A1 (en) * | 2006-06-19 | 2008-05-29 | Jingwen Liu | Hypolipidemic and/or hypocholesteremic compounds obtainable from the goldenseal plant |
EP2043628A4 (en) * | 2006-06-27 | 2009-11-25 | Riolan Technologies Inc | Ultraviolet absorbing ophthalmic compositions |
US20110064605A1 (en) * | 2006-07-05 | 2011-03-17 | Thermapure, Inc. | Method for treating an object contaminated with harmful biological organisms or chemical substances utilizing electromagnetic waves |
EP1882473A1 (en) * | 2006-07-28 | 2008-01-30 | Indena S.P.A. | Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs |
KR100878053B1 (en) | 2007-07-10 | 2009-01-15 | 김인숙 | Antibacterial contact lens compring naringin and process for preparing the same |
EA015401B1 (en) * | 2008-01-15 | 2011-08-30 | Эльмар Мустафа Оглы Касимов | Ophthalmatic medical film and method of producing thereof |
US8163358B2 (en) | 2009-02-18 | 2012-04-24 | Synergeyes, Inc. | Surface modification of contact lenses |
ES2366839B1 (en) * | 2010-04-12 | 2012-07-12 | Angel Nestares Guerrero | COMPOSITION FOR THE CARE OF CONTACT LENSES |
MX341220B (en) * | 2010-05-24 | 2016-08-10 | Indena Spa | Tamarind seed polysaccharide for use in the treatment of microbial infections. |
ITMI20110336A1 (en) * | 2011-03-04 | 2012-09-05 | I R B Istituto Di Ricerche B Iotecnologiche S R L | COMPOSITIONS AND OPHTHALMIC DEVICES CONTAINING PLANT STEM CELLS |
TWI480039B (en) * | 2011-03-10 | 2015-04-11 | Pegavision Corp | Aqueous composition for contact lens |
JP2011209757A (en) * | 2011-07-06 | 2011-10-20 | Rohto Pharmaceutical Co Ltd | Method and composition for care of contact lens |
US20150099020A1 (en) | 2012-05-14 | 2015-04-09 | Nordichug Oy | Aqueous disinfectant composition |
US8726539B2 (en) | 2012-09-18 | 2014-05-20 | Cambridge Engineering, Inc. | Heater and controls for extraction of moisture and biological organisms from structures |
WO2016184998A1 (en) | 2015-05-21 | 2016-11-24 | Ophtalmis Monaco | Combination of lipoic acid and taurine as osmoprotective agent |
CA2985014C (en) | 2015-05-21 | 2024-01-16 | Ophtalmis Monaco | Ophthalmic composition comprising lipoic acid and a mucomimetic polymer |
BR112019016988B1 (en) * | 2017-02-17 | 2023-02-23 | Diversey, Inc | PEROXIDE-BASED DISINFECTING SOLUTIONS CONTAINING INORGANIC SALTS, METHOD FOR DISINFECTING OR SANITIZING A SURFACE |
CN108997575B (en) * | 2018-07-18 | 2020-12-15 | 苏州大学 | Polyethylene glycol-b-polytyrosine-lipoic acid copolymer, polypeptide micelle and preparation method and application thereof |
KR101978624B1 (en) * | 2019-01-15 | 2019-05-14 | 전북대학교산학협력단 | Composition for treatment and prevention of dry eye syndrome comprising aucubin |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943251A (en) * | 1973-06-27 | 1976-03-09 | Medow Norman B | Ophthamological use of hydrastis compounds |
FR2426698A2 (en) * | 1970-12-09 | 1979-12-21 | Rosenberg Edy | Sodium salt of naringin prepn. - from naringin and sodium hydroxide in alcohol, used for treating circulatory and ophthalmic disorders |
WO1992021049A1 (en) * | 1991-05-10 | 1992-11-26 | Allergan, Inc. | Methods and compositions for inhibiting deposit formation on contact lenses |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
WO1994000160A1 (en) * | 1992-06-29 | 1994-01-06 | Allergan, Inc. | Ophthalmic compositions and methods for preserving and using same |
WO1996006603A1 (en) * | 1994-08-26 | 1996-03-07 | Alcon Laboratories, Inc. | Polyalkylene oxide containing quaternary ammonium antimicrobial agents |
US5591773A (en) * | 1994-03-14 | 1997-01-07 | The Trustees Of Columbia University In The City Of New York | Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters |
WO1997041215A1 (en) * | 1996-04-29 | 1997-11-06 | Novo Nordisk A/S | Non-aqueous, liquid, enzyme-containing compositions |
US5691379A (en) * | 1993-05-22 | 1997-11-25 | Asta Medica Aktiengesellschaft | Dihydrolipoic acid as an ophthalmological agent to suppress intolerance reactions in the area between implants and living body tissue |
EP0812592A1 (en) * | 1996-06-10 | 1997-12-17 | Kikkoman Corporation | An agent for the prevention or treatment of cataracts |
WO1999023887A1 (en) * | 1997-11-10 | 1999-05-20 | Novo Nordisk A/S | Antimicrobial activity of laccases |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136173A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Mixed xanthan gum and locust beam gum therapeutic compositions |
US4394381A (en) * | 1979-04-13 | 1983-07-19 | George F. And Irene Sherrill 1978 Trust No. 1 | Method for the relief of pain |
US4820352A (en) * | 1983-01-10 | 1989-04-11 | Bausch & Lomb Incorporated | Cleaning and conditioning solutions for contact lenses and methods of use |
JPS6038323A (en) * | 1983-08-10 | 1985-02-27 | Sankyo Co Ltd | Ophthalmic anti-inflammatory agent |
DE3416209A1 (en) * | 1984-05-02 | 1985-11-21 | Mohamed Roshdy Dr Ismail | EYE TREATMENT PREPARATIONS |
US4836986A (en) * | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
US4758595A (en) * | 1984-12-11 | 1988-07-19 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
JPH0696521B2 (en) * | 1986-01-31 | 1994-11-30 | 千寿製薬株式会社 | Ocular hypotensive agent for topical ocular administration |
EP0277270B1 (en) * | 1986-08-07 | 1996-12-27 | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG | N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions |
US5624958A (en) * | 1987-12-31 | 1997-04-29 | Isaacs; Charles E. | Disinfecting contact lenses |
US5175161A (en) * | 1989-04-06 | 1992-12-29 | Sankyo Company, Limited | Occular hypotensive agents |
US4997626A (en) * | 1990-01-05 | 1991-03-05 | Allergan, Inc. | Methods to disinfect contact lenses |
US5078908A (en) * | 1989-10-02 | 1992-01-07 | Allergan, Inc. | Methods for generating chlorine dioxide and compositions for disinfecting |
US5279673A (en) * | 1990-01-05 | 1994-01-18 | Allergan, Inc. | Methods to disinfect contact lenses |
US5300296A (en) * | 1989-11-06 | 1994-04-05 | Frank J. Holly | Antimicrobial agent for opthalmic formulations |
GB9002422D0 (en) * | 1990-02-03 | 1990-04-04 | Boots Co Plc | Anti-microbial compositions |
US6355684B1 (en) * | 1990-10-11 | 2002-03-12 | Meryl J. Squires | Antimicrobial treatment for herpes simplex virus and other infectious diseases |
US5661130A (en) * | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
US5547990A (en) * | 1994-05-20 | 1996-08-20 | Lonza, Inc. | Disinfectants and sanitizers with reduced eye irritation potential |
US5945446A (en) * | 1997-02-10 | 1999-08-31 | Laubc Biochemicals, Corporation | Process for preparing synthetic soil-extract materials and medicaments based thereon |
US5817630A (en) * | 1997-03-18 | 1998-10-06 | Austin Nutriceutical Corporation | Glutathione antioxidant eye drops |
-
1998
- 1998-08-06 US US09/130,542 patent/US6162393A/en not_active Expired - Lifetime
-
1999
- 1999-08-05 WO PCT/US1999/017853 patent/WO2000007634A1/en active IP Right Grant
- 1999-08-05 EP EP03011083A patent/EP1336415A3/en not_active Withdrawn
- 1999-08-05 EP EP99940927A patent/EP1102602B1/en not_active Expired - Lifetime
- 1999-08-05 CA CA002339635A patent/CA2339635A1/en not_active Abandoned
- 1999-08-05 AU AU54686/99A patent/AU764906B2/en not_active Ceased
- 1999-08-05 AT AT99940927T patent/ATE264697T1/en not_active IP Right Cessation
- 1999-08-05 JP JP2000563316A patent/JP2002522120A/en active Pending
- 1999-08-05 DE DE69916620T patent/DE69916620D1/en not_active Expired - Lifetime
-
2000
- 2000-11-13 US US09/711,784 patent/US6793941B1/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2426698A2 (en) * | 1970-12-09 | 1979-12-21 | Rosenberg Edy | Sodium salt of naringin prepn. - from naringin and sodium hydroxide in alcohol, used for treating circulatory and ophthalmic disorders |
US3943251A (en) * | 1973-06-27 | 1976-03-09 | Medow Norman B | Ophthamological use of hydrastis compounds |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
WO1992021049A1 (en) * | 1991-05-10 | 1992-11-26 | Allergan, Inc. | Methods and compositions for inhibiting deposit formation on contact lenses |
WO1994000160A1 (en) * | 1992-06-29 | 1994-01-06 | Allergan, Inc. | Ophthalmic compositions and methods for preserving and using same |
US5691379A (en) * | 1993-05-22 | 1997-11-25 | Asta Medica Aktiengesellschaft | Dihydrolipoic acid as an ophthalmological agent to suppress intolerance reactions in the area between implants and living body tissue |
US5591773A (en) * | 1994-03-14 | 1997-01-07 | The Trustees Of Columbia University In The City Of New York | Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters |
WO1996006603A1 (en) * | 1994-08-26 | 1996-03-07 | Alcon Laboratories, Inc. | Polyalkylene oxide containing quaternary ammonium antimicrobial agents |
WO1997041215A1 (en) * | 1996-04-29 | 1997-11-06 | Novo Nordisk A/S | Non-aqueous, liquid, enzyme-containing compositions |
EP0812592A1 (en) * | 1996-06-10 | 1997-12-17 | Kikkoman Corporation | An agent for the prevention or treatment of cataracts |
WO1999023887A1 (en) * | 1997-11-10 | 1999-05-20 | Novo Nordisk A/S | Antimicrobial activity of laccases |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002161038A (en) * | 2000-09-14 | 2002-06-04 | Hayashibara Biochem Lab Inc | Ophthalmic pharmaceutical composition |
US9492582B2 (en) | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
US9913474B2 (en) | 2000-11-08 | 2018-03-13 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
US10595532B2 (en) | 2000-11-08 | 2020-03-24 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
US9308264B2 (en) | 2000-11-08 | 2016-04-12 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
US10531663B2 (en) | 2000-11-08 | 2020-01-14 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
EP1339418A4 (en) * | 2000-11-08 | 2005-06-08 | Bio Concept Lab | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
US10244760B2 (en) | 2000-11-08 | 2019-04-02 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
US10064410B2 (en) | 2000-11-08 | 2018-09-04 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
EP1339418A1 (en) * | 2000-11-08 | 2003-09-03 | Bio-Concept Laboratories | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
US9585394B2 (en) | 2000-11-08 | 2017-03-07 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
US9492581B2 (en) | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
JP2004526186A (en) * | 2000-11-08 | 2004-08-26 | バイオ−コンセプト・ラボラトリーズ | Improved ophthalmic and contact lens solutions containing vitamin B forms |
EP1353709A1 (en) | 2001-01-12 | 2003-10-22 | Novartis AG | Lens care product containing dexpanthenol |
JP2002326941A (en) * | 2001-05-01 | 2002-11-15 | Naomasa Morita | Agent for ophthalmic use |
WO2003086442A3 (en) * | 2002-04-04 | 2004-03-18 | Natural Disinfectant Technolog | Ophthalmic, pharmaceutical and other healthcare preparations with naturally occuring plant compounds, extracts and derivatives |
EP2377543A3 (en) * | 2002-04-04 | 2012-04-18 | Natural Disinfectant Technologies | Ophthalmic, pharmaceutical and other healthcare preparations with naturally ocurring plant compounds, extracts and derivatives |
WO2006039460A3 (en) * | 2004-09-29 | 2006-09-28 | Bausch & Lomb | Contact lens with biocidal activity, process of manufacture, use of the contact lens, and kit |
WO2006039460A2 (en) * | 2004-09-29 | 2006-04-13 | Bausch & Lomb Incorporated | Contact lens with biocidal activity, process of manufacture, use of the contact lens, and kit |
EP1905443A4 (en) * | 2005-06-08 | 2009-12-16 | Cellex K K | Liquid for preventing tissue adhesion and method of preventing tissue adhesion |
EP1905443A1 (en) * | 2005-06-08 | 2008-04-02 | Cellex K.K. | Liquid for preventing tissue adhesion and method of preventing tissue adhesion |
US9155751B2 (en) | 2005-06-08 | 2015-10-13 | The University Of Tokyo | Solution for tissue adhesion prevention and method for tissue adhesion prevention |
Also Published As
Publication number | Publication date |
---|---|
AU5468699A (en) | 2000-02-28 |
US6162393A (en) | 2000-12-19 |
DE69916620D1 (en) | 2004-05-27 |
CA2339635A1 (en) | 2000-02-17 |
EP1102602B1 (en) | 2004-04-21 |
US6793941B1 (en) | 2004-09-21 |
EP1102602A1 (en) | 2001-05-30 |
AU764906B2 (en) | 2003-09-04 |
ATE264697T1 (en) | 2004-05-15 |
EP1336415A3 (en) | 2004-07-28 |
JP2002522120A (en) | 2002-07-23 |
EP1336415A2 (en) | 2003-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6162393A (en) | Contact lens and ophthalmic solutions | |
US6143244A (en) | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant and a complementary phosphate-borate buffer system | |
KR100246904B1 (en) | Preservative system for ophthalmic and contact lens solutions and method for cleaning, disinfecting and storing contact lenses | |
EP1030692B1 (en) | Treatment of contact lenses with aqueous solution comprising an alkali carbonate | |
EP2130527B1 (en) | Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid | |
EP1140224B1 (en) | Contact lens cleaner comprising biguanide, tyloxapol and poloxamine | |
US20030086986A1 (en) | Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives | |
EP1976571A1 (en) | Improving disinfection efficacy of lens care regimen for rigid gas permeable contact lenses | |
US9125405B2 (en) | Contact lens solution with a tertiary amine oxide | |
US8889160B2 (en) | Ophthalmic compositions with biguanide and PEG-glycerol esters | |
EP2262521B1 (en) | Ophthalmic compositions comprising a dipeptide with a glycine moiety | |
MXPA00004563A (en) | Treatment of contact lenses with aqueous solution comprising an alkali carbonate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 54686/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2339635 Country of ref document: CA Ref country code: CA Ref document number: 2339635 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999940927 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999940927 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 54686/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999940927 Country of ref document: EP |